[
  {
    "ts": null,
    "headline": "3 Stocks Seeing Insider Buys: CNC, PFE, BMY",
    "summary": "Investors can see insider buys as an overall net positive concerning the longer-term outlook for a stock.",
    "url": "https://finnhub.io/api/news?id=e46c046c1ceaf5425547ced00f3ce400599f0e15c65f542e18a01c320094a08c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731454800,
      "headline": "3 Stocks Seeing Insider Buys: CNC, PFE, BMY",
      "id": 131315773,
      "image": "https://media.zenfs.com/en/zacks.com/b56da65365e8609db11bbb1e13b32e44",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Investors can see insider buys as an overall net positive concerning the longer-term outlook for a stock.",
      "url": "https://finnhub.io/api/news?id=e46c046c1ceaf5425547ced00f3ce400599f0e15c65f542e18a01c320094a08c"
    }
  },
  {
    "ts": null,
    "headline": "Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results",
    "summary": "Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously treated metastatic melanoma, based on preliminary results presented at the 21st International Congress of the Society of Melanoma Research in OctoberPresenting initial results from the company-sponsored Phase 1/2a study of [212Pb]VMT-α-NET in patients with RPT-naïve neuroendocrine tumors at the upcoming 2024 North American Neuroendocrine Tumor Society Sy",
    "url": "https://finnhub.io/api/news?id=2ff2b6a58a54c89aa302a01f5b5de4799965c1ffa071caee6095bd27ac292f0f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731445500,
      "headline": "Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results",
      "id": 131311544,
      "image": "https://media.zenfs.com/en/globenewswire.com/838f217da615df0b6c09f0e2557cd05f",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously treated metastatic melanoma, based on preliminary results presented at the 21st International Congress of the Society of Melanoma Research in OctoberPresenting initial results from the company-sponsored Phase 1/2a study of [212Pb]VMT-α-NET in patients with RPT-naïve neuroendocrine tumors at the upcoming 2024 North American Neuroendocrine Tumor Society Sy",
      "url": "https://finnhub.io/api/news?id=2ff2b6a58a54c89aa302a01f5b5de4799965c1ffa071caee6095bd27ac292f0f"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=e963a254ef660c7d5e645c97e1f5732cba54113f94cd3d4f805f9f83d9410b91",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731429660,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day",
      "id": 131417103,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=e963a254ef660c7d5e645c97e1f5732cba54113f94cd3d4f805f9f83d9410b91"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains",
    "summary": "ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY stock rises.",
    "url": "https://finnhub.io/api/news?id=895d02b89eb8f0172499b0b91e516997d8c75fa2e2578f890cfaa8c6d774e46a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731421800,
      "headline": "AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains",
      "id": 131307308,
      "image": "https://media.zenfs.com/en/zacks.com/6c915f5bdd1c7ea850acb1ca1c067326",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY stock rises.",
      "url": "https://finnhub.io/api/news?id=895d02b89eb8f0172499b0b91e516997d8c75fa2e2578f890cfaa8c6d774e46a"
    }
  },
  {
    "ts": null,
    "headline": "Leerink Partners Upgrades Bristol-Myers Squibb (BMY)",
    "summary": "Leerink Partners Upgrades Bristol-Myers Squibb (BMY)",
    "url": "https://finnhub.io/api/news?id=2309dff9467a49cade812e55ab84c565bd35d77f54288a018d680109d5482d94",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731420087,
      "headline": "Leerink Partners Upgrades Bristol-Myers Squibb (BMY)",
      "id": 131304978,
      "image": "",
      "related": "BMY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2309dff9467a49cade812e55ab84c565bd35d77f54288a018d680109d5482d94"
    }
  },
  {
    "ts": null,
    "headline": "What the NFL Draft Can Teach Investors About Big Pharma",
    "summary": "Few would think professional sports leagues and the drug-development industry have much in common.  When it comes to building up a pipeline, though, there is a striking similarity with valuable insights for executives on the prowl for deals.  The news sent  Bristol-Myers Squibb  which recently won approval for a rival schizophrenia treatment, surging 10.5%.",
    "url": "https://finnhub.io/api/news?id=fb96284f076122f497644372259fac4d72cfc5bec6077b656a0a282867b3c025",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731412800,
      "headline": "What the NFL Draft Can Teach Investors About Big Pharma",
      "id": 131303725,
      "image": "https://s.yimg.com/ny/api/res/1.2/OmwPjA5LcyCFJCoZS8tKeg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/9b8068ac62f13fd1d160b58ad3379941",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Few would think professional sports leagues and the drug-development industry have much in common.  When it comes to building up a pipeline, though, there is a striking similarity with valuable insights for executives on the prowl for deals.  The news sent  Bristol-Myers Squibb  which recently won approval for a rival schizophrenia treatment, surging 10.5%.",
      "url": "https://finnhub.io/api/news?id=fb96284f076122f497644372259fac4d72cfc5bec6077b656a0a282867b3c025"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say",
    "summary": "AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say",
    "url": "https://finnhub.io/api/news?id=03726f73b83aa7d3d1100520fcc059ba94db53d03f85e1a6077034c7714ead98",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731401580,
      "headline": "AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say",
      "id": 131414143,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say",
      "url": "https://finnhub.io/api/news?id=03726f73b83aa7d3d1100520fcc059ba94db53d03f85e1a6077034c7714ead98"
    }
  }
]